These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Chemical Development of Therapeutic Oligonucleotides. Lundin KE; Gissberg O; Smith CIE; Zain R Methods Mol Biol; 2019; 2036():3-16. PubMed ID: 31410788 [TBL] [Abstract][Full Text] [Related]
23. Nucleic acids as therapeutic agents. Alvarez-Salas LM Curr Top Med Chem; 2008; 8(15):1379-404. PubMed ID: 18991725 [TBL] [Abstract][Full Text] [Related]
24. Application of peptide nucleic acid in cancer therapy. Knudsen H; Nielsen PE Anticancer Drugs; 1997 Feb; 8(2):113-8. PubMed ID: 9073307 [TBL] [Abstract][Full Text] [Related]
25. Nucleic acid aptamers as tools and drugs: recent developments. Rimmele M Chembiochem; 2003 Oct; 4(10):963-71. PubMed ID: 14523912 [TBL] [Abstract][Full Text] [Related]
26. RNA as a target for developing antivirals. McKnight KL; Heinz BA Antivir Chem Chemother; 2003 Mar; 14(2):61-73. PubMed ID: 12856917 [TBL] [Abstract][Full Text] [Related]
27. Introduction and History of the Chemistry of Nucleic Acids Therapeutics. Gait MJ; Agrawal S Methods Mol Biol; 2022; 2434():3-31. PubMed ID: 35213007 [TBL] [Abstract][Full Text] [Related]
28. The current landscape of nucleic acid therapeutics. Kulkarni JA; Witzigmann D; Thomson SB; Chen S; Leavitt BR; Cullis PR; van der Meel R Nat Nanotechnol; 2021 Jun; 16(6):630-643. PubMed ID: 34059811 [TBL] [Abstract][Full Text] [Related]
29. Anti-HIV inhibitors based on nucleic acids: emergence of aptamers as potent antivirals. Joshi PJ; Fisher TS; Prasad VR Curr Drug Targets Infect Disord; 2003 Dec; 3(4):383-400. PubMed ID: 14754437 [TBL] [Abstract][Full Text] [Related]
34. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. Xu L; Anchordoquy T J Pharm Sci; 2011 Jan; 100(1):38-52. PubMed ID: 20575003 [TBL] [Abstract][Full Text] [Related]
35. Oligonucleotides as antivirals: dream or realistic perspective? Van Aerschot A Antiviral Res; 2006 Sep; 71(2-3):307-16. PubMed ID: 16621039 [TBL] [Abstract][Full Text] [Related]
36. Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection. Vaillant A Antiviral Res; 2016 Sep; 133():32-40. PubMed ID: 27400989 [TBL] [Abstract][Full Text] [Related]
37. Strategies to identify potential therapeutic target sites in RNA. Lützelberger M; Kjems J Handb Exp Pharmacol; 2006; (173):243-59. PubMed ID: 16594619 [TBL] [Abstract][Full Text] [Related]
38. The versatility of oligonucleotides as potential therapeutics. Eckstein F Expert Opin Biol Ther; 2007 Jul; 7(7):1021-34. PubMed ID: 17665991 [TBL] [Abstract][Full Text] [Related]
39. Therapeutic potential and mechanism of action of oligonucleotides and ribozymes. Lavrovsky Y; Chen S; Roy AK Biochem Mol Med; 1997 Oct; 62(1):11-22. PubMed ID: 9367793 [TBL] [Abstract][Full Text] [Related]
40. Sense antisense nonantisense. Can these novel antivirals knock HIV senseless? Chang HE; Mascolini M J Int Assoc Physicians AIDS Care; 1995 Feb; 1(1):11-8. PubMed ID: 11362229 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]